How should a healthy adult female with documented low testosterone or hypoactive sexual desire disorder use a 0.2% testosterone cream transdermally, including dosing, application site, monitoring, and contraindications?

Testosterone 0.2% Cream for Women: Clinical Use Guidelines

For postmenopausal women with hypoactive sexual desire disorder (HSDD), testosterone 0.2% cream can be used off-label at doses that maintain physiologic premenopausal testosterone levels (typically 10 mg daily applied transdermally), but this concentration is not specifically validated in major guidelines and requires careful monitoring to avoid supraphysiologic levels. 1

Patient Selection

Only prescribe testosterone for postmenopausal women with HSDD after formal biopsychosocial assessment - this is the sole evidence-based indication 1, 2. Do not use testosterone for:

• Healthy women without documented HSDD
• Infertility, cognitive dysfunction, cardiovascular health, bone health, or general well-being 2
• Women with high cardiometabolic disease risk (safety data excluded these patients from trials) 1

Contraindications

• Pregnancy or breastfeeding
• Breast or endometrial cancer
• Cardiovascular disease (insufficient safety data) 1
• Women not in stable relationships or with untreated depression/relationship problems 3

Dosing and Application

Concentration and Amount

The 0.2% concentration you mention is higher than the standard studied formulations. Most evidence supports:

• 10 mg daily (equivalent to 2 cm of Andro-Feme cream in one study) 3
• Target physiologic premenopausal testosterone range, not supraphysiologic levels 1

Application Site

• Upper arms and shoulders are preferred sites 4
• Apply to clean, dry, intact skin
• Avoid abdomen - this site showed higher transfer risk to partners 4
• Rotate application sites if needed

Application Instructions

• Wash hands immediately after application (reduces residual testosterone by 96%) 4
• Cover application site with clothing (t-shirt reduces partner transfer from 280% increase to only 6-11% increase in partner testosterone) 4
• Wait at least 2 hours before skin-to-skin contact with others 4
• Showering 10+ hours post-application has no effect on absorption; showering at 2-6 hours reduces absorption by 12-13% 4

Monitoring Protocol

Baseline (Before Starting)

• Measure total testosterone level 1, 2
• Document HSDD symptoms using validated tools (Brief Index of Sexual Function for Women, Profile of Female Sexual Function) 3, 5
• Obtain informed consent discussing off-label use, benefits, and risks 6

Follow-up Schedule

1. 3-6 weeks after initiation: Check total testosterone to assess for overuse and ensure levels remain in physiologic premenopausal range 1, 2

2. Every 6 months ongoing:

   • Monitor testosterone levels to screen for overuse 1, 2
   • Assess clinical response and signs of androgen excess (acne, hirsutism, voice deepening, clitoromegaly) 1
   • Discontinue if no benefit by 6 months 1

3. Maximum treatment duration: Safety data only available for 24 months; long-term safety beyond this is unknown 1

Critical Warnings About Compounded Products

Compounded "bioidentical" testosterone preparations (which 0.2% cream may be) cannot be recommended due to lack of efficacy and safety data 1. If using compounded products because approved formulations are unavailable:

• Ensure pharmacy complies with Good Manufacturing Practice standards 1
• Verify purity of Active Pharmaceutical Ingredients 1
• Limit dosing to achieve physiologic premenopausal testosterone concentrations 1

Avoid preparations causing supraphysiologic levels (pellets, injections) - these are explicitly not recommended 1

Evidence Quality Note

The 0.2% concentration specifically lacks validation in high-quality trials. The strongest evidence supports:

• 300 µg/day transdermal patches (multiple RCTs) 5
• 10 mg daily cream (one RCT showing improved sexual desire, frequency, receptivity) 3

Your 0.2% cream concentration would deliver variable amounts depending on application volume, making precise dosing difficult and increasing risk of supraphysiologic levels.

Practical Algorithm

1. Confirm postmenopausal status + HSDD diagnosis after biopsychosocial assessment
2. Exclude contraindications and modifiable factors
3. Obtain baseline testosterone level
4. Start with lowest effective dose (aim for ~10 mg daily equivalent)
5. Recheck testosterone at 3-6 weeks - adjust dose to maintain physiologic range
6. If no improvement by 6 months → discontinue
7. If effective → continue with 6-month monitoring, maximum 24 months documented safety

The lack of FDA-approved female testosterone formulations in the US remains a significant barrier to evidence-based care 6, 7. When using male formulations or compounded products off-label, meticulous dose adjustment and monitoring are essential to avoid androgen excess while achieving therapeutic benefit.